Los ordenadores principales de las naves espaciales necesitan procesadores que puedan soportar el duro ambiente que reina fuera de la Tierra, por lo que utilizan chips desarrollados hace años que son robustos y fiables bajo tales condiciones, si bien su capacidad de computación siempre …
Nuevo procesador para ordenadores ubicados fuera de la Tierra Read More »
Con enjambres de pequeños drones sería posible lograr una inspección automática y barata de cultivos en invernaderos. La mayor parte de las tecnologías necesarias para ello ya existen y son asequibles. Sin embargo, la capacidad de un dron para orientarse todav&iacu …
The Trump administration continues to open the doors to the cheap, high-deductible coverage, to the worry of insurance experts and stakeholders in the healthcare industry.
Embecta bought the company, which has an auto-injector platform, to expand outside of diabetes care.
Embecta closes Owen Mumford acquisition for up to $201M Read More »
The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional payments totaling $3 billion.
Boston Scientific buys $1.5B stake in TAVR developer MiRus Read More »
A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said Revolution Medicines “is evolving into a major revenue-generating oncology company,” and projects an approval in second-line disease by the end of the third quarter.
Is Revolution ‘the next oncology titan’? Truist analysts make the case Read More »
The test will enable physicians to assess if post-surgery cancer patients need to receive treatment to minimize the risk of recurrence.
Natera wins FDA approval for companion diagnostic Read More »
Right after reporting a major Phase 3 LAG-3 miss that has rattled analysts, Regeneron Pharmaceuticals revealed a back-loaded partnership with Parabilis Medicines aimed at adding a new drug class to its early-stage pipeline.
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B Read More »
Providers are reaping high award amounts, and arbiters have “structural conflicts of interest” that incentivize a high volume of disputes, driving up healthcare costs for employers and patients, the groups wrote.
Baxfendy, the first aldosterone synthase inhibitor to be approved by the FDA for high blood pressure, is among the products AstraZeneca is relying on to hit its 2030 goal of $80 billion in revenue.
AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs Read More »
